Novartis: Galvus lowers blood sugar with fewer side effects

By Elaine Rigoli

Tampa, Fla., Sept. 14 - Novartis AG said Galvus (vildagliptin), submitted for approval in the United States and European Union as a once-daily oral treatment for type 2 diabetes, has demonstrated impressive efficacy and an attractive tolerability profile that may benefit many people currently struggling to control their disease.

The data found that Galvus shows equivalent efficacy to the diabetes medicine rosiglitazone, an insulin sensitizer known as a thiazolidinedione, in a head-to-head monotherapy phase 3 study that led to an overall 1.8% reduction in blood sugar levels as measured by HbA1c.

The Basel, Switzerland biopharmaceutical company said results were achieved without weight gain overall and with a lower incidence of edema (fluid retention) - both of which are side effects commonly associated with thiazolidinediones.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.